{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:28:21Z","timestamp":1765960101851,"version":"3.44.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24 AR069760"],"award-info":[{"award-number":["K24 AR069760"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jid.2020.04.007","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T21:26:50Z","timestamp":1588022810000},"page":"2353-2358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-8623","authenticated-orcid":false,"given":"Afton","family":"Chavez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-9126","authenticated-orcid":false,"suffix":"Jr.","given":"Charles P.","family":"Quesenberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4390-1445","authenticated-orcid":false,"given":"Jeanne","family":"Darbinian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-3475","authenticated-orcid":false,"given":"Maryam M.","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.04.007_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/1756283X16644247","article-title":"Epigenetic therapy in gastrointestinal cancer: the right combination","volume":"9","author":"Abdelfatah","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jid.2020.04.007_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/CMR.0000000000000087","article-title":"Comparing characteristics of melanoma cases arising in health maintenance organizations with state and national registries","volume":"24","author":"Asgari","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2020.04.007_bib3","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth","volume":"55","author":"Bergman","year":"2012","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jid.2020.04.007_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2015.5866","article-title":"The association between psychiatric disorders and frequent indoor tanning","volume":"152","author":"Blashill","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2020.04.007_bib5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1586\/14737140.2014.940329","article-title":"Could valproic acid be an effective anticancer agent? The evidence so far","volume":"14","author":"Brodie","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jid.2020.04.007_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/epi.13261","article-title":"Epilepsy, seizures, physical exercise, and sports: a report from the ILAE Task Force on Sports and Epilepsy","volume":"57","author":"Capovilla","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.jid.2020.04.007_bib7","first-page":"917","article-title":"Effect of valproic acid on the proliferation and apoptosis of the human melanoma G-361 cell line","volume":"71","author":"Chodurek","year":"2014","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.jid.2020.04.007_bib8","first-page":"1298","article-title":"Valproic acid enhances cisplatin cytotoxicity in melanoma cells","volume":"69","author":"Chodurek","year":"2012","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.jid.2020.04.007_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/CAD.0b013e32835dc7c5","article-title":"Valproic acid reduces the tolerability of Temsirolimus in children with solid tumors","volume":"24","author":"Coulter","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jid.2020.04.007_bib10","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-08-1931","article-title":"Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I\/II clinical trial","volume":"15","author":"Daud","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2020.04.007_bib11","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2020.04.007_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.cmr.0000129576.49313.26","article-title":"Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival","volume":"14","author":"Fl\u00f8renes","year":"2004","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2020.04.007_bib13","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/ijc.22401","article-title":"Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood","volume":"120","author":"Furchert","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2020.04.007_bib14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.lungcan.2015.10.008","article-title":"Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer","volume":"90","author":"Gerber","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jid.2020.04.007_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7812\/TPP\/15-225","article-title":"The Kaiser Permanente northern California adult member health survey","volume":"20","author":"Gordon","year":"2016","journal-title":"Perm J"},{"key":"10.1016\/j.jid.2020.04.007_bib16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1158\/1055-9965.EPI-08-0646","article-title":"Cancer risk in long-term users of valproate: a population-based case-control study","volume":"18","author":"Hallas","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl. 18","key":"10.1016\/j.jid.2020.04.007_bib17","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.1200\/jco.2006.24.18_suppl.8044","article-title":"A\u00a0phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma","volume":"24","author":"Hauschild","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.04.007_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2018.07.057","article-title":"Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer","volume":"835","author":"Heers","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jid.2020.04.007_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fonc.2017.00095","article-title":"Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca2+ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK","volume":"7","author":"Heged\u00fcs","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2020.04.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-017-0434-3","article-title":"Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines","volume":"10","author":"H\u00f6lscher","year":"2018","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jid.2020.04.007_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/exd.13089","article-title":"Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside","volume":"25","author":"Hornig","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2020.04.007_bib22","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.4049\/jimmunol.1302532","article-title":"Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL\/DR5 pathway","volume":"192","author":"Jazirehi","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2020.04.007_bib23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Landreville","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2020.04.007_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ije\/dyn040","article-title":"Cohort Profile: the Diabetes Study of Northern California (DISTANCE)--objectives and design of a survey follow-up study of social health disparities in a managed care population","volume":"38","author":"Moffet","year":"2009","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jid.2020.04.007_bib25","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.21873\/anticanres.12665","article-title":"The role of histone deacetylase inhibitors in uveal melanoma: current evidence","volume":"38","author":"Moschos","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jid.2020.04.007_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/abbs\/gmr032","article-title":"Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment","volume":"43","author":"Ouyang","year":"2011","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.jid.2020.04.007_bib28","first-page":"535","article-title":"Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells","volume":"30","author":"Papi","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jid.2020.04.007_bib29","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2020.04.007_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.bjc.6604817","article-title":"A\u00a0phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma","volume":"100","author":"Rocca","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jid.2020.04.007_bib31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1248\/bpb.b16-01025","article-title":"Histone deacetylase inhibitors sensitize murine B16F10 melanoma cells to carbon ion irradiation by inducing G1 phase arrest","volume":"40","author":"Saito","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jid.2020.04.007_bib32","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1158\/1078-0432.CCR-05-2849","article-title":"Valproic acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts","volume":"12","author":"Shu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2020.04.007_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1078-0432.CCR-10-0738","article-title":"Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children\u2019s oncology group report","volume":"17","author":"Su","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2020.04.007_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"3","author":"Tan","year":"2010","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jid.2020.04.007_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4161\/cbt.6.2.3578","article-title":"Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells","volume":"6","author":"Valentini","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jid.2020.04.007_bib36","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.molonc.2015.04.002","article-title":"Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation","volume":"9","author":"Woan","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jid.2020.04.007_bib37","first-page":"1056","article-title":"Antiproliferative effect of valproic acid and 5,7-dimethoxycoumarin against A2058 human melanoma cells","volume":"71","author":"Wolny","year":"2014","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.jid.2020.04.007_bib38","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ncomms2489","article-title":"PI(4,5)P2 5-phosphatase A regulates PI3K\/Akt signalling and has a tumour suppressive role in human melanoma","volume":"4","author":"Ye","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2020.04.007_bib39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1535-7163.425.3.4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells","volume":"3","author":"Zhang","year":"2004","journal-title":"Mol Cancer Ther"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20314020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20314020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:20:16Z","timestamp":1758302416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20314020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0022202X20314020"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.04.007","relation":{},"ISSN":["0022-202X"],"issn-type":[{"type":"print","value":"0022-202X"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}